CNBC's Jim Cramer discusses news Regeneron's drug Eylea for treating diabetic macular edema created significantly greater improvement in visual acuity compared with Lucentis.» Read More
July 15- Hewlett-Packard Co interim Chairman and activist investor Ralph Whitworth will step down on Wednesday to focus on his health, the latest top-level departure from the computer maker as it struggles to return to consistent growth.
July 15- Hewlett-Packard Co interim chairman and activist investor Ralph Whitworth will step down on Wednesday to focus on his health, the latest top-level departure from the computer maker as it struggles to return to consistent growth.
July 15- Hewlett-Packard Co said interim Chairman Ralph Whitworth resigned from its board of directors, effective Wednesday, to focus on his health. Relational Investors said co-founder Whitworth was taking a leave of absence from the hedge fund and it wished "his family all the best at this difficult time."
July 14- Several multi-billion dollar deals and bids have made 2014 a busy year for healthcare acquisitions, despite Pfizer pulling its $118 billion offer for AstraZeneca.
*Move aimed towards making drugs more affordable in India. MUMBAI, July 14- India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..
MUMBAI, July 14- India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd..
July 11- Big Pharma companies are trying to offload low-growth, mature drug portfolios to firms such as Blackstone Group LP and TPG Capital LP which need to figure out how to carve them out, in one of private equity's greatest dealmaking challenges.
PARIS, July 11- The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.
Some of the names on the move ahead of the open.
*European shares dip, Wall Street expected to follow. LONDON, July 7- The dollar and world shares were losing steam on Monday as the momentum from last week's strong U.S. jobs data faded and attention began to turn to the fast-approaching earnings season.
*Total, Sanofi fall after cautioning over results. Some analysts said that while Europe's stock market rally could flatline in the near term, the longer-term outlook remained positive given steps taken by the European Central Bank to boost the region's economy. A fall in the shares of heavyweight stocks Total and Sanofi also pegged back European markets.
LONDON, July 7- The dollar was on its strongest run since late October on Monday as the momentum of last week's stellar U.S. jobs data carried markets towards what will be a crucial earnings season for record high shares.
*FTSEurofirst 300 down 0.1 pct, Euro STOXX 50 down 0.2 pct. *Total, Sanofi fall after cautioning over results. EDINBURGH, July 7- European shares fell on Monday after weak data out of Germany took the wind out of a rally that saw a top index post its best week in over three months.
EDINBURGH, July 7- European shares fell on Monday after weak data out of Germany took the wind out of a rally that saw a top index post its best week in over three months. German industrial output fell 1.8 percent on the month in May, its biggest drop in more than 2 years, confounding expectations of unchanged industrial output in Europe's powerhouse.
Pfizer paid a "nominal fee" to cover expenses related to the facility inspection, and to obtain a certification, a Pfizer spokeswoman said.
*Sanofi hit may be limited as EU market smaller than U.S. LONDON, June 27- European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015..
Some of Friday's midday movers:
As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.
NEW YORK, June 16- Morgan Stanley, an adviser to Valeant Pharmaceuticals International Inc in its $53 billion hostile bid for Allergan Inc, initially tried to get hired by Allergan and in its pitch called the unsolicited bidder a "house of cards", according to Allergan.
PARIS, June 14- French drugmaker Sanofi said on Saturday it was teaming up with U.S. medical device maker Medtronic in diabetes. Under the terms of a memorandum of understanding, Sanofi and Medtronic will initially cooperate on developing drug-device combinations and offering care management services for diabetes patients.